Recent news highlights Alnylam's advances in Q3 financial results, positive Phase 1b clinical data for ALN-HTT02, and ongoing Phase 3 trials for nucresiran. The company is described as solidly profitable with active investor engagement through earnings calls.

• Alnylam Pharmaceuticals reported advances in its Q3 bottom line results, reflecting ongoing financial progress [N1].
• The company held a Q3 2026 earnings conference call to discuss recent performance and outlook [N2].
• Analysts provided insights on key performance measures ahead of the Q3 earnings release [N3].
• Positive initial Phase 1b results were reported for ALN-HTT02, an investigational RNAi therapeutic [N5].
• Alnylam is described as solidly profitable, with discussions on investor perceptions of the biotech sector [N7].
• The company is conducting Phase 3 clinical trials for nucresiran in hereditary transthyretin amyloidosis indications [N6].

Alnylam's extensive portfolio of approved RNAi therapeutics and a broad pipeline of clinical-stage programs across diverse indications provide multiple potential growth drivers. The company's 2030 strategy outlines ambitious goals for market leadership in transthyretin amyloidosis and expansion into new tissue types and diseases. Positive clinical trial results and regulatory approvals support pipeline advancement. Strong financial liquidity and profitability provide resources for sustained R&D investment and commercialization efforts. Collaborations with Roche and Regeneron offer additional development and market access opportunities.

Risks include the inherent uncertainties of clinical development, regulatory approvals, and market acceptance for RNAi therapeutics. Competition from other modalities and companies targeting similar diseases may impact market share. Dependence on collaborations for certain products introduces execution risks. The company's financial performance could be affected by pricing pressures, reimbursement challenges, and potential adverse events in clinical trials. Convertible debt and credit facility obligations require ongoing financial discipline. Market volatility and investor sentiment toward biotechnology stocks may influence perception and capital access.

Alnylam's moat is built on its pioneering RNAi technology platform, which enables targeted gene silencing with potential to address diseases at the genetic root cause. The company has established multiple first-in-class RNAi therapeutics with regulatory approvals across major markets, creating barriers to entry through intellectual property, clinical expertise, and regulatory experience. Strategic collaborations with large pharmaceutical companies enhance development and commercialization capabilities. Its focus on genetically validated targets and advanced delivery methods further strengthens its competitive position in the biotechnology sector.

• Clinical and Regulatory Risk: Clinical trials may fail to demonstrate safety or efficacy, delaying or preventing regulatory approvals for pipeline products.
• Competitive Risk: Emerging therapies and alternative modalities could reduce market share for Alnylam's RNAi therapeutics.
• Collaboration Risk: Dependence on partners like Novartis, Sanofi, Roche, and Regeneron introduces risks related to coordination, priorities, and commercialization.
• Financial Risk: Convertible notes and revolving credit facility obligations require careful financial management to maintain liquidity and flexibility.
• Market and Reimbursement Risk: Pricing pressures and reimbursement challenges could impact revenue and profitability.

• Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company pioneering RNA interference (RNAi) therapeutics, which silence messenger RNA to prevent disease-causing proteins from being made [S1].
• The company has six approved RNAi-based medicines: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), Leqvio (inclisiran), and Qfitlia (fitusiran) [S1].
• AMVUTTRA is approved for hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy and cardiomyopathy in multiple regions including the US, EU, UK, Japan, Brazil, and Canada [S1].
• ONPATTRO is approved for hATTR amyloidosis with polyneuropathy and cardiomyopathy in the US, EU, Japan, and Brazil [S1].
• GIVLAARI is approved for acute hepatic porphyria (AHP) in adults and adolescents in the US, EU, and other countries [S1].
• OXLUMO is approved for primary hyperoxaluria type 1 (PH1) in pediatric and adult patients in the US, EU, and UK [S1].
• Leqvio (inclisiran) is commercialized by Novartis and approved for hypercholesterolemia and mixed dyslipidemia in multiple countries including the US, EU, China, and Japan [S1].
• Qfitlia (fitusiran) is commercialized by Genzyme (Sanofi) and approved for prophylaxis in hemophilia A or B patients in the US and China [S1].
• The company has a research and development strategy targeting genetically validated genes with high unmet medical need, using GalNAc conjugate or lipid nanoparticle delivery for liver, and alternative conjugates for CNS and ocular delivery [S1].
• Alnylam launched its 'Alnylam 2030' strategy aiming for global leadership in TTR therapies, expansion to 10 tissue types and over 40 clinical programs, and sustained profitable growth with 25%+ revenue CAGR and ~30% non-GAAP operating margin by 2030 [S1].
• Nucresiran, a next-generation RNAi therapeutic for ATTR amyloidosis, is in Phase 3 trials for polyneuropathy and cardiomyopathy indications [S1].
• Zilebesiran, targeting angiotensinogen for hypertension, is in a Phase 3 cardiovascular outcomes trial (ZENITH) in collaboration with Roche [S1].
• Mivelsiran, targeting amyloid precursor protein for cerebral amyloid angiopathy and Alzheimer's disease, is in Phase 1 and Phase 2 clinical trials [S1].
• Cemdisiran, developed with Regeneron, is in Phase 3 trials for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria and myasthenia gravis [S1].
• The company issued $661.3 million of 0.00% Convertible Senior Notes due 2028 and repurchased a portion of 2027 Notes, maintaining capped call transactions to reduce dilution risk [S1].
• Alnylam has a $500 million revolving credit facility maturing in 2030, secured by substantially all assets and subject to customary covenants [S1].
• As of September 30, 2026, Alnylam reported $1.754 billion in cash and equivalents, $5.113 billion in current assets, $2.063 billion in current liabilities, a current ratio of 2.48, and a cash ratio of 0.85 [S2].
• Net income for the quarter ended September 30, 2026, was $2.167 billion with basic EPS of $16.19 and diluted EPS of $15.72 [S2].
• Revenue reported for fiscal year 2022 was approximately $1.037 billion [S2].
• Recent news highlights include advances in Q3 bottom line results, positive Phase 1b results for ALN-HTT02, and ongoing Phase 3 trials for nucresiran [N1][N5].
• Alnylam is described as solidly profitable with ongoing investor interest and active earnings conference calls [N7][N2].